Literature DB >> 27607138

Validated guidelines for tumor delineation on magnetic resonance imaging for laryngeal and hypopharyngeal cancer.

Elise Anne Jager1, Hans Ligtenberg1, Joana Caldas-Magalhaes1, Tim Schakel1, Marielle E Philippens1, Frank A Pameijer2, Nicolien Kasperts1, Stefan M Willems3, Christiaan H Terhaard1, Cornelis P Raaijmakers1.   

Abstract

BACKGROUND: Validation of magnetic resonance imaging (MRI) and development of guidelines for the delineation of the gross tumor volume (GTV) is of utmost importance to benefit from the visibility of anatomical details on MR images and to achieve an accurate GTV delineation. In the ideal situation, the GTV delineation corresponds to the histopathologically determined 'true tumor volume'. Consequently, we developed guidelines for GTV delineation of laryngeal and hypopharyngeal tumors on MRI and determined the accuracy of the resulting delineation of the tumor outline on histopathology as gold standard.
MATERIAL AND METHODS: Twenty-seven patients with T3 or T4 laryngeal/hypopharyngeal cancer underwent a MRI scan before laryngectomy. Hematoxylin and eosin sections were obtained from surgical specimens and tumor was delineated by one pathologist. GTV was delineated on MR images by three independent observers in two sessions. The first session (del1) was performed according to clinical practice. In the second session (del2) guidelines were used. The reconstructed specimen was registered to the MR images for comparison of the delineated GTVs to the tumor on histopathology. Volumes and overlap parameters were analyzed. A target margin needed to assure tumor coverage was determined.
RESULTS: The median GTVs (del1: 19.4 cm3, del2: 15.8 cm3) were larger than the tumor volume on pathology (10.5 cm3). Comparable target margins were needed for both delineation sessions to assure tumor coverage. By adding these margins to the GTVs, the target volumes for del1 (median: 81.3 cm3) were significantly larger than for del2 (median: 64.2 cm3) (p ≤ 0.0001) with similar tumor coverage.
CONCLUSIONS: In clinical radiotherapy practice, the delineated GTV on MRI is twice as large as the tumor volume. Validated delineation guidelines lead to a significant decrease in the overestimation of the tumor volume.

Entities:  

Mesh:

Year:  2016        PMID: 27607138     DOI: 10.1080/0284186X.2016.1219048

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

Review 1.  Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer.

Authors:  Mischa de Ridder; Cornelis P J Raaijmakers; Frank A Pameijer; Remco de Bree; Floris C J Reinders; Patricia A H Doornaert; Chris H J Terhaard; Marielle E P Philippens
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study.

Authors:  Carlos E Cardenas; Sanne E Blinde; Abdallah S R Mohamed; Sweet Ping Ng; Cornelis Raaijmakers; Marielle Philippens; Alexis Kotte; Abrahim A Al-Mamgani; Irene Karam; David J Thomson; Jared Robbins; Kate Newbold; Clifton D Fuller; Chris Terhaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-02-04       Impact factor: 8.013

3.  Target Volume Delineation Using Diffusion-weighted Imaging for MR-guided Radiotherapy: A Case Series of Laryngeal Cancer Validated by Pathology.

Authors:  Hans Ligtenberg; Tim Schakel; Jan Willem Dankbaar; Lilian N Ruiter; Boris Peltenburg; Stefan M Willems; Nicolien Kasperts; Chris H J Terhaard; Cornelis P J Raaijmakers; Marielle E P Philippens
Journal:  Cureus       Date:  2018-04-11

4.  CTV Guidance for Head and Neck Cancers.

Authors:  Beth M Beadle; Carryn M Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-15       Impact factor: 7.038

5.  Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin.

Authors:  Hans Ligtenberg; Stefan M Willems; Lilian N Ruiter; Elise Anne Jager; Chris H J Terhaard; Cornelis P J Raaijmakers; Marielle E P Philippens
Journal:  Clin Transl Radiat Oncol       Date:  2018-07-11

6.  Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases.

Authors:  Sweet Ping Ng; Carlos E Cardenas; Hesham Elhalawani; Courtney Pollard; Baher Elgohari; Penny Fang; Mohamed Meheissen; Nandita Guha-Thakurta; Houda Bahig; Jason M Johnson; Mona Kamal; Adam S Garden; Jay P Reddy; Shirley Y Su; Renata Ferrarotto; Steven J Frank; G Brandon Gunn; Amy C Moreno; David I Rosenthal; Clifton D Fuller; Jack Phan
Journal:  Phys Imaging Radiat Oncol       Date:  2020-04-29

7.  MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges.

Authors:  Simon Boeke; David Mönnich; Janita E van Timmeren; Panagiotis Balermpas
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

8.  Delineation uncertainties of tumour volumes on MRI of head and neck cancer patients.

Authors:  Ruta Zukauskaite; Christopher N Rumley; Christian R Hansen; Michael G Jameson; Yuvnik Trada; Jørgen Johansen; Niels Gyldenkerne; Jesper G Eriksen; Farhannah Aly; Rasmus L Christensen; Mark Lee; Carsten Brink; Lois Holloway
Journal:  Clin Transl Radiat Oncol       Date:  2022-08-06

9.  Exploring the impact of metabolic imaging in head and neck cancer treatment.

Authors:  Diana Raquel Dias Domingues; Michelle M Leech
Journal:  Head Neck       Date:  2022-07-01       Impact factor: 3.821

10.  Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT.

Authors:  Sophie E Vollenbrock; Marlies E Nowee; Francine E M Voncken; Alexis N T J Kotte; Lucas Goense; Peter S N van Rossum; Astrid L H M W van Lier; Stijn W Heijmink; Annemarieke Bartels-Rutten; Frank J Wessels; Berthe M P Aleman; Luc Dewit; Linda G W Kerkmeijer; Edwin P M Jansen; Martijn Intven; Irene M Lips; Gert J Meijer; Jasper Nijkamp
Journal:  Adv Radiat Oncol       Date:  2019-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.